CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Brivaracetamdrug
Likely dose
Brivaracetam 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03405714
NCT03405714Phase 2Completed
CompareCT.gov

A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month < 16 Years of Age With Epilepsy

UCB Biopharma S.P.R.L.·interventional·Posted Jan 23, 2018·Updated May 11, 2022

In Brief

A Phase 2 clinical trial evaluating Brivaracetam for Epilepsy. Completed, enrolled 50 participants across 17 sites in 7 countries.

Detailed Summary

The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) administered intravenously (iv) in subjects \>= 1 month to \< 16 years of age with epilepsy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesCzechia, Germany, Hungary, Italy, Mexico, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 23, 2018
Enrollment StartJun 1, 2018
Primary CompletionNov 4, 2020
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.4 years ago

Interventions

Brivaracetamdrug

* Pharmaceutical form: Solution for iv injection * Route of administration: intravenous use * Concentration: 10 mg/ml